SLC50A1 and hepatocellular carcinoma: In conclusion, these results suggest that SLC50A1 modulates HCC proliferation by impacting the glycolytic pathway, and that 2-DG effectively inhibits liver cancer cell proliferation both in vitro and in vivo.